Latest News & Features
Americas
Those working in the field of genetic sequence must clearly understand the subtleties of sequence searching, in order to avoid the risks of infringement and invalidity, as Ellen Sherin of GQ Life Sciences finds out. 26 October 2017
Big Pharma
Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe. 26 October 2017
Americas
Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications. 24 October 2017
Big Pharma
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the
developing challenges facing patentability in the life sciences field. 24 October 2017
Americas
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados. 24 October 2017
Big Pharma
If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports. 10 October 2017
article
Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper. 2 October 2017
Americas
With discussions underway to create a CRISPR patent pool, Kevin O’Connor of Neal, Gerber & Eisenberg discusses the three main perspectives when considering the main benefits of such a move. 15 September 2017
Americas
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner. 30 August 2017
Americas
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law. 12 July 2017